Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO 2019 Expert Video Report on Carcinoma of Unknown Primary

Reporting from ESMO 2019 Congress, George Pentheroudakis comments on the results from studies evaluating 2 different management strategies in patients with visceral carcinoma of unknown primary: one with molecular testing to determine personalised treatment based on tissue origin, and the second to select the targeted approach based on testing of actionable molecular aberrations suitable for targeted therapy.

Abstracts:

  • LBA15_PR: A phase 3 trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04)
  • 1983PD_PR: Comprehensive genomic profiling (CGP) of carcinoma of unknown primary origin (CUP): Retrospective molecular classification of potentially eligible patients (pts) for targeted or immunotherapy treatment (tx) using the prospective CUPISCO trial’s criteria

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings